Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi®, is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company’s lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, ‘EVOGUARD.’

Biotechnology

Evofem Biosciences

Saundra Pelletier

Danielle M. Adams

Gaelle Saint-Louis

David Friend

Damian Frantz

Ram Gupta

Jamilyn Perez-aragon

Ellen Harris

Amy Raskopf

Ivy Zhang

Tammy Forrester

Kathy Gallo-Doyle

Deedee Asuamah

Ellen Thomas

Richard Murawski

Robin Belsaas

Catherine Maher

Leadership Team

Directors

Operations Team

Regulatory Affairs and Market Access

Teams at Evofem Biosciences

Leadership Team

Directors

Operations Team

Regulatory Affairs and Market Access